Should the LIFE Trial Assess Improvement in Ejection Fraction as a Primary Endpoint?

Adam Ioannou; Sofia Metaxa; Steny Simon; Amit K.J. Mandal; Constantinos G. Missouris

doi:10.1016/j.jchf.2020.07.006

Should the LIFE Trial Assess Improvement in Ejection Fraction as a Primary Endpoint?

Adam Ioannou
, Sofia Metaxa
, Steny Simon
, Amit K.J. Mandal
, Constantinos G. Missouris

Medical School

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	959-960
Number of pages	2
Journal	JACC: Heart Failure
Volume	8
Issue number	11
DOIs	https://doi.org/10.1016/j.jchf.2020.07.006
Publication status	Published - Nov 2020

Access to Document

10.1016/j.jchf.2020.07.006

Cite this

@article{6aad14676b52470a97ef2be3a62a1639,

title = "Should the LIFE Trial Assess Improvement in Ejection Fraction as a Primary Endpoint?",

author = "Adam Ioannou and Sofia Metaxa and Steny Simon and Mandal, \{Amit K.J.\} and Missouris, \{Constantinos G.\}",

year = "2020",

month = nov,

doi = "10.1016/j.jchf.2020.07.006",

language = "English",

volume = "8",

pages = "959--960",

journal = "JACC: Heart Failure",

issn = "2213-1779",